Haleos Labs Ltd

Fri 3/07/2026,11:36:48 | NSE : HALEOSLABS

₹1637.106.20 (0.38%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1630.00

Previous Close

₹ 1630.90

Volume

255

Mkt Cap ( Rs. Cr)

₹494.94

High

₹ 1651.20

Low

₹ 1630.00

52 Week High

₹ 1774.00

52 Week Low

₹ 1067.00

Book Value Per Share

₹ 706.34

Dividend Yield

0.09

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Haleos Labs Ltd

Your Vote -

Buy

38.64%

Hold

11.36%

Sell

50.00%

38.64%

44 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

50%

Sell Order Quantity

50%

Bid Price

Qty

1637.70

1

1637.00

4

1636.00

1

1634.00

9

1633.00

10

Bid Total

3001

Bid Price

Qty

1648.20

1

1648.00

5

1649.00

4

1650.00

1

1651.00

1

Bid Total

2984

Option Chain

Analyzes market sentiment, predicts Haleos Labs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Haleos Labs - Trading Window

    18 Jun 2026, 1:42PM HALEOS LABS LIMITED has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

  • Haleos Labs - Updates

    16 Jun 2026, 6:45PM HALEOS LABS LIMITED has informed the Exchange regarding 'Transfer Of Shares (IEPF Suspense Account)'.

  • Haleos Labs - Transfer Of Shares (IEPF Suspense Account)

    16 Jun 2026, 6:28PM Communication to shareholders regarding transfer of shares to the IEPF suspense account for the unclaimed dividend for the year 2018-19.

  • Haleos Labs - Disclosure under SEBI Takeover Regulations

    12 Jun 2026, 8:12PM TVVSN Murthy has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acqu

  • Haleos Labs - Updates

    2 Jun 2026, 3:39PM HALEOS LABS LIMITED has informed the Exchange regarding 'Sub-Committees Of Board (Reconstitution)'.

  • Haleos Labs - Copy of Newspaper Publication

    2 Jun 2026, 3:14PM HALEOS LABS LIMITED has informed the Exchange about Copy of Newspaper Publication

  • Haleos Labs - Sub-Committees Of Board (Reconstitution)

    2 Jun 2026, 3:36PM In lieu of change in Board composition, the Board Committees are reconstituted.

  • Haleos Labs - Newspaper Publication (Financial Results)

    2 Jun 2026, 3:01PM Enclosed - newspaper advertisement for Q4 results.

  • Haleos Labs - Financial Results (Q4/F26)

    30 May 2026, 2:24PM Enclosed financial results for the quarter and year ended 31st March, 2026.

  • Haleos Labs - Announcement under Regulation 30 (LODR)-Change in Management

    29 May 2026, 8:11PM Reappointment of Mrs Sudeepthi Gopineedi as whole-time Director for a further period of 5 years w.e.f. Sept 2, 2026, subject to approval of Shareholde

  • Haleos Labs - Auditors Appointment

    29 May 2026, 8:07PM Enclosed are the details related to the appointment of Statutory Auditors and Cost Auditors.

  • Haleos Labs - Announcement under Regulation 30 (LODR)-Resignation of Director

    29 May 2026, 8:02PM Resignation of Mrs. Sundaramma Patilbandla from the post of Independent Director w.e.f. May 29, 2026.

  • Haleos Labs Q4 net profit down 16.79% at Rs 2.23 cr

    29 May 2026, 6:30PM The company reported standalone net profit of Rs 2.23 crore for the quarter ended March 31, 2026 as compared to Rs 2.68 crore in the same period last

  • Haleos Labs - Board Meeting Outcome for Meeting Held On May 26, 2026

    29 May 2026, 3:49PM Enclosed - Outcome of 97th Board meeting.

  • Haleos Labs - Updates

    25 May 2026, 5:01PM HALEOS LABS LIMITED has informed the Exchange regarding 'Saksham Niveshak'.

  • Haleos Labs - Saksham Niveshak

    25 May 2026, 4:54PM Request shareholders to update their KYC details (reminder no. 6) and information about the second 100-day campaign from April 1, 2026 to July 9, 2026

  • Haleos Labs - Board Meeting Intimation for 97Th Board Meeting (29.05.2026)

    22 May 2026, 7:13PM Haleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and appr

  • Haleos Labs - Credit Rating

    22 May 2026, 3:19PM HALEOS LABS LIMITED has informed the Exchange about Credit Rating

  • Haleos Labs - Announcement under Regulation 30 (LODR)-Credit Rating

    22 May 2026, 3:10PM Credit rating of the Company and its material subsidiary.

  • Haleos Labs - Shareholders meeting

    1 May 2026, 9:28AM HALEOS LABS LIMITED has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding v

  • Haleos Labs has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    16 Apr 2026, 2:30PM As of March 2026, 72.10% is owned by Indian Promoters and 27.89% by Public. <p align=justify> Top five Promoters holding highest number of shares of H

  • Haleos Labs - Updates

    8 Apr 2026, 7:05PM HALEOS LABS LIMITED has informed the Exchange regarding 'Encumbrance (Annual Disclosure)'.

  • Haleos Labs - Encumbrance (Annual Disclosure)

    8 Apr 2026, 7:02PM Disclosure related to the non-encumbrance of shares received from promoters.

  • Haleos Labs - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2026, 1:33PM HALEOS LABS LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Haleos Labs - Updates

    8 Apr 2026, 11:53AM HALEOS LABS LIMITED has informed the Exchange regarding 'Annual Confirmation (Reclassification)'.

  • Haleos Labs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2026, 1:31PM Enclosed - RTA certificate.

  • Haleos Labs - Annual Confirmation (Reclassification)

    8 Apr 2026, 11:50AM Confirmation received from the erstwhile Promoter group.

  • SMS Pharma receives non-exclusive license to manufacture & supply Molnupiravir

    20 Jan 2022 , 3:43PM Molnupiravir is the first oral, direct-acting antivral shown to be highly effective at reducing infectious virus
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Haleos Labs Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 307.6849 276.348 264.957 249.1726 210.9553
Liabilities 307.6849 276.348 264.957 249.1726 210.9553
Equity 3.0233 3.0233 3.0233 3.0233 3.0233
Gross Profit 40.4682 44.2317 34.4313 26.4065 31.3647
Net Profit 17.7768 21.3708 13.0654 13.2176 25.3813
Cash From Operating Activities 38.4304 28.0325 14.7514 4.5753 -14.6554
NPM(%) 5.9 6.41 4.35 4.19 7.34
Revenue 300.9896 333.371 300.0016 315.2418 345.6281
Expenses 260.5214 289.1393 265.5703 288.8353 314.2634
ROE(%) 8.32 10 6.11 6.18 11.88

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
1.5 15 0.09 1581.3
1.5 15 0.09 1373.4
23 Sep 2024 1.5 15 0.09 696.3
22 Sep 2022 1.5 15 0.09 637.6
20 Sep 2021 1.5 15 0.09 659.8
19 Sep 2019 1.5 15 0.09 483.4

Peers

Other companies within the same industry or sector that are comparable to Haleos Labs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 718.45 0.44 0.00 930.65 -26.19 0.70
Lotus Eye Hospital and Institute Ltd 129.95 3.47 4331.67 3391.15 0.39 0.00
Vaishali Pharma Ltd 7.35 0.41 23.71 21273.80 15.96 0.00
Astec Lifesciences Ltd 716.00 -0.82 0.00 3197.93 -363.14 0.00

Company Info

SMS Lifesciences India Limited incorporated under the provisions of the Companies Act, 1956, on 31st day of May, 2006, originally as Private Limited Company in the name of "Potluri Real Estate Private Limited" and subsequently changed its name to "Potluri Packaging Industries Private Limited" on 6th November, 2013. Thereafter the Company had changed its name as "SMS Lifesciences India Private Limited" on 4th August, 2014 and subsequently converted as Public Limited Company with effect from 22nd June, 2016 and its Corporate Identity No. is U74930TG2006PLC050223. The Company is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, Active Pharmaceutical Ingredients (API) and Intermediates. 2020 -Company has received the prestigious award in the 5th edition of India Pharma and Medical Device 2020.

SMS Lifesciences India Limited incorporated under the provisions of the Companies Act, 1956, on 31st day of May, 2006, originally as Private Limited Company in the name of "Potluri Real Estate Private Limited" and subsequently changed its name to "Potluri Packaging Industries Private Limited" on 6th November, 2013. Thereafter the Company had changed its name as "SMS Lifesciences India Private Limited" on 4th August, 2014 and subsequently converted as Public Limited Company with effect from 22nd June, 2016 and its Corporate Identity No. is U74930TG2006PLC050223. The Company is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, Active Pharmaceutical Ingredients (API) and Intermediates. 2020 -Company has received the prestigious award in the 5th edition of India Pharma and Medical Device 2020.

Parent Organisation

Haleos Labs Ltd.

Founded

31/05/2006

Managing Director

Mr.TVVSN Murthy

NSE Symbol

HALEOSLABSEQ

FAQ